In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 201 to 210 of 294

TitleTypeExpected publication date
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
Pharmalgen for the treatment of bee and wasp venom allergyTechnology appraisal guidanceTBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]Technology appraisal guidanceTBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidance
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidance
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidanceTBC
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]Technology appraisal guidanceTBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All